2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
28
Prostatic Neoplasms
16
Carcinoma, Non-Small-Cell Lung
10
Sarcoma
9
Lung Neoplasms
6
Uterine Cervical Neoplasms
5
Endometrial Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Neoplasms
3
Liposarcoma, Myxoid
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Carcinoma In Situ
3
Urogenital Neoplasms
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma, Synovial
2
Radiation Injuries
2
Neurofibrosarcoma
2
Neoplasm Metastasis
2
Melanoma
2
Lymphatic Metastasis
2
Liposarcoma
2
Leiomyosarcoma
2
Histiocytoma, Malignant Fibrous
2
Fibrosarcoma
2
Cholangiocarcinoma
2
Interventions
padeliporfin
5
Abiraterone Acetate
3
Pluvicto
2
Paclitaxel
2
sipuleucel-T
1
rucaparib
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
onapristone
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
ixabepilone
1
gallium 68 PSMA-11
1
apalutamide
1
abiraterone
1
Therapeutics
1
Suspensions
1
Radiotherapy
1
Radiation Dose Hypofractionation
1
Powders
1
Nivolumab
1
Leuprolide
1
Ipilimumab
1
Imatinib Mesylate
1
Gemcitabine
1
EPI-506
1
Cisplatin
1
Chemical Fractionation
1
Biopsy, Needle
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genital Neoplasms, Male
×
Radiation Dose Hypofractionation
×
Clear all
NCT02319239
2020-10-28
ESKO
Tampere University Hospital
Phase NA
Completed
80 enrolled